Sage Journals: Discover world-class research

Abstract

Background:

OBE001 is a novel, orally active nonpeptide oxytocin receptor antagonist under development for the treatment of preterm labor and improvement in embryo implantation and pregnancy rate in assisted reproductive technology (ART). The reproductive safety of OBE001 was evaluated in customized fertility embryonic development (FER)/early embryonic development (EED) and fetal development (FD) and pre/postnatal development (PPN) studies mimicking clinical exposure scenarios.

Methods:

Oral OBE001 was evaluated at doses of 37.5, 75, and 125 mg/kg/d in female rats during a FER/EED study (from premating to implantation) and throughout FD during a FD/PPN study.

Results:

No OBE001 effects were observed during the FER/EED study. The FD/PPN study did not result in adverse OBE001 effects in females allowed to litter, their offspring, and second-generation fetuses. Females at 125 mg/kg/d who underwent cesarean section before term had slight reductions in body weights and food consumption, and associated fetuses had slightly delayed ossification of skull bones, which was not adverse in the absence of effects on live offspring.

Conclusion:

OBE001 at up to 125 mg/kg/d had no effects on EED and no adverse effects on FD and postnatal development of rats. These results constitute an important step toward the development of OBE001 in preterm labor and ART indications.

Keywords

preterm labor assisted reproductive technology OBE001 reproductive safety rat

Get full access to this article

View all access options for this article.

References

ClinicalTrials.gov . OBE001 Phase 2 Dose-finding Study Versus Placebo in Women Undergoing Embryo Transfer in the Context of IVF-ICSI (IMPLANT). 2015. Web site. https://clinicaltrials.gov/ct2/show/NCT02310802?term=obseva&rank=1. Accessed September 15, 2015.

ClinicalTrials.gov. A Phase 2 Study of OBE001 Versus Placebo in the Delay of Preterm Birth (TERM). 2015. Web site. https://clinicaltrials.gov/ct2/show?term=obseva&rank=2. Accessed September 15, 2015.

Howson

Kinney

McDougall

Lawn

. Born too soon: preterm birth matters. Reprod Health. 2013;10(suppl 1):S1.

Vrachnis

Malamas

Sifakis

Deligeoroglou

Iliodromiti

. The oxytocin-oxytocin receptor system and its antagonists as tocolytic agents. Int J Endocrinol. 2011;2011:350546.

Cirillo

Gillio Tos

Schwarz

. Pharmacology of (2S,4Z)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino)-1-[(2′-methyl[1,1′-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamide, a new potent and selective nonpeptide antagonist of the oxytocin receptor. J Pharmacol Exp Ther. 2003 Jul;306(1):253–261.

Romero

Sibai

Sanchez-Ramos

. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double-blind, placebo-controlled trial with tocolytic rescue. Am J Obstet Gynecol. 2000;182(5):1173–1183.

Thornton

Vatish

Slater

. Oxytocin antagonists: clinical and scientific considerations. Exp Physiol. 2001;86(2):297–302.

Ayoubi

Epiney

Brioschi

Fanchin

Chardonnens

de Ziegler

. Comparison of changes in uterine contraction frequency after ovulation in the menstrual cycle and in in vitro fertilization cycles. Fertil Steril. 2003;79(5):1101–1105.

Fanchin

Righini

Olivennes

Taylor

de Ziegler

Frydman

. Uterine contractions at the time of embryo transfer alter pregnancy rates after in-vitro fertilization. Hum Reprod. 1998;13(7):1968–1974.

10.

Zhu

Che

Xiao

. Uterine peristalsis before embryo transfer affects the chance of clinical pregnancy in fresh and frozen-thawed embryo transfer cycles. Hum Reprod. 2014;29(6):1238–1243.

11.

Moraloglu

Tonguc

Var

Zeyrek

Batioglu

. Treatment with oxytocin antagonists before embryo transfer may increase implantation rates after IVF. Reprod Biomed Online. 2010;21(3):338–343.

12.

Pohl

Homery

Lemaux

Patat

Chollet

. Pharmacokinetic interactions of OBE001 and betamethasone in healthy female volunteers. J Clin Pharm Ther. 2015;40(3):328–332.

13.

International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH M3 (R2)—Guideline on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals. 2009. Web site. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Multidisciplinary/M3_R2/Step4/M3_R2__Guideline.pdf. Accessed September 15, 2015.

14.

ICH Harmonised Tripartite Guideline. Part I: Detection of Toxicity to Reproduction for Medicinal Products (24 June 1993). In: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH S5(R2)—Detection of Toxicity to Reproduction for Medicinal Products and Toxicity to Male Fertility. 2005. Web site. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S5/Step4/S5_R2__Guideline.pdf. Accessed September 15, 2015.

15.

Staples

. Teratogens and the delaney clause. Science. 1974;185(4154):813–814.

16.

Wilson

. Embryological considerations in teratology. Ann N Y Acad Sci. 1965;123:219–227.

17.

Sharma

Lee

Gao

Steele

. Toxicity profile of solvents by aspiration approach for topical agent delivery to respiratory tract epithelium. Int J Toxicol. 2011;30(3):358–366.

18.

Delongeas

de Conchard

Beamonte

. Assessment of Labrasol/Labrafil/Transcutol (4/4/2, v/v/v) as a non-clinical vehicle for poorly water-soluble compounds after 4-week oral toxicity study in Wistar rats. Regul Toxicol Pharmacol. 2010;57(2-3):284–290.

19.

Healing

Sulemann

Cotton

. Safety data on 19 vehicles for use in 1 month oral rodent pre-clinical studies: administration of hydroxypropyl-ß-cyclodextrin causes renal toxicity [published online May 10, 2015]. J Appl Toxicol. 2015. doi:10.1002/jat.3155.

20.

Bailey

Wise

Buschmann

Hurtt

Fisher

. Pre- and postnatal developmental toxicity study design for pharmaceuticals. Birth Defects Res B Dev Reprod Toxicol. 2009;86(6):437–445.

21.

Aliverti

Bonanomi

Giavini

Leone

Mariani

. The extent of fetal ossification as an index of delayed development in teratogenic studies on the rat. Teratology. 1979;20(2):237–242.

22.

Destexhe

Stannard

Wilby

. Nonclinical reproductive and developmental safety evaluation of the MAGE-A3 Cancer Immunotherapeutic, a therapeutic vaccine for cancer treatment. Reprod Toxicol. 2015;51:90–105.

23.

McAnulty

Burns

. Evaluation of the maternal and neonatal effects of the oxytocin antagonist, atosiban, in a cross-fostering study in rats. Reprod Toxicol. 2004;19(1):65–70.

24.

EMEA. Tractocile: EPAR. 2004. Web site. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000253/WC500040491.pdf. Accessed June 06, 2015.

25.

McGovern

Llorens

Skurnick

Weiss

Goldsmith

. Increased risk of preterm birth in singleton pregnancies resulting from in vitro fertilization-embryo transfer or gamete intrafallopian transfer: a meta-analysis. Fertil Steril. 2004;82(6):1514–1520.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.04 MB